Collectively, the activation of endothelial KCa3.1, along with KCa2.3 channels by SKA-31 and related compounds may represent a novel pharmacological strategy for lowering peripheral vascular resistance that may be beneficial in hypertension or ischaemic heart disease. Here, KCNN3 is linked to hypertensive disorder.